Historically, the use of upfront chemotherapy in advanced prostate cancer has faced significant challenges. But recent research results showing that systemic chemotherapy improves overall survival in patients with metastatic castration-resistant prostate cancer have changed the thinking about its use.
Stereotactic body radiation therapy and proton beam therapy have theoretical advantages over the current standard of care, intensity-modulated radiation therapy. Clinical trials will be important to determine their value.
Robotic radical perineal prostatectomy (RPP) may prove to be a minimally invasive solution for the treatment of localized prostate cancer, shortening operative time and reducing blood loss compared with open RPP. It may be especially advantageous in certain populations, such as those who have had previous abdominal surgery.
A novel metabolite of an approved agent for metastatic prostate cancer, Δ4-abiraterone, may be more effective than the parent drug, abiraterone, Cleveland Clinic researchers have found. They now will examine how D4A may prolong survival.
A review of oncologic outcomes, toxicity and complications in Cleveland Clinic Florida patients who underwent either salvage robotic prostatectomy or salvage cryotherapy identified some apparent pluses for prostatectomy.
Using the new 4Kscore test after a positive result from a traditional PSA test can reduce the number of prostate biopsies by 30 to 50 percent while still accurately identifying high-grade cancers.
Commercialization of a medical product is a complex undertaking that requires expert oversight, rigorous assessment and perseverance. Here’s an insider’s perspective.
Unlike radiation therapy and surgical extirpation for prostate cancer, cryosurgery has lacked an established biochemical standard that defines treatment success. After six years of work, Cleveland Clinic researchers have developed an evidence-based definition that can inform ongoing treatment decisions.
At the 2015 ASCO GU Cancers Symposium, Cleveland Clinic researchers and their colleagues report that the small molecule inhibitor tivantinib improves progression-free survival in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.
Normal saline hydrodissection of the anterior rectal wall increases the safety of prostate cryoablation, further decreasing the likelihood of procedure-related complications even in the more difficult post-radiation salvage-cryoablation setting.